Mikawa K, Nishina K, Maekawa N, Obara H
Department of Anaesthesiology, Kobe University School of Medicine, Japan.
Br J Anaesth. 1996 Feb;76(2):221-6. doi: 10.1093/bja/76.2.221.
We have compared the efficacy of three calcium channel blockers, nicardipine, diltiazem and verapamil, in attenuating the cardiovascular responses to laryngoscopy and intubation in 60 normotensive patients (ASA I) undergoing rapid sequence induction of anaesthesia with thiopentone and fentanyl. We also examined whether or not these blockers inhibited catecholamine release induced by intubation. The patients were allocated to one of four groups (n = 15 for each): saline (control), nicardipine 30 micrograms kg-1, diltiazem 0.2 mg kg-1 or verapamil 0.1 mg kg-1. Verapamil and the three other drugs were administered 45 s and 60 s before the start of direct laryngoscopy, respectively, in a double-dummy design. Anaesthesia was induced with thiopentone 4 mg kg-1 i.v. and fentanyl 2 micrograms kg-1 i.v. Tracheal intubation was facilitated with vecuronium 0.2 mg kg-1. During anaesthesia, ventilation was assisted or controlled with 1% isoflurane and 50% nitrous oxide in oxygen. Laryngoscopy lasting 30 s was attempted 2 min after administration of thiopentone and vecuronium. Patients receiving saline exhibited significant increases in systolic and diastolic arterial pressures (AP), heart rate (HR) and plasma concentrations of catecholamines associated with tracheal intubation. The increase in AP was attenuated in patients treated with any calcium channel blocker. The greatest effect was elicited by verapamil, which attenuated the increase in HR, although nicardipine seemed to enhance tachycardia. All three drugs failed to suppress the increase in plasma catecholamine concentrations in response to tracheal intubation. These findings suggest that bolus injection of verapamil 0.1 mg kg-1 was a more effective method of controlling hypertension and tachycardia associated with intubation than diltiazem 0.2 mg kg-1 or nicardipine 30 micrograms kg-1, and that these prophylactic effects were not caused by inhibition of the catecholamine response.
我们比较了三种钙通道阻滞剂(尼卡地平、地尔硫䓬和维拉帕米)对60例接受硫喷妥钠和芬太尼快速顺序诱导麻醉的血压正常患者(ASA I级)喉镜检查和气管插管时心血管反应的减弱效果。我们还研究了这些阻滞剂是否抑制气管插管诱导的儿茶酚胺释放。患者被分为四组之一(每组n = 15):生理盐水(对照组)、尼卡地平30微克/千克、地尔硫䓬0.2毫克/千克或维拉帕米0.1毫克/千克。采用双盲设计,维拉帕米和其他三种药物分别在直接喉镜检查开始前45秒和60秒给药。静脉注射硫喷妥钠4毫克/千克和芬太尼2微克/千克诱导麻醉。使用维库溴铵0.2毫克/千克辅助气管插管。麻醉期间,用1%异氟醚和50%氧化亚氮与氧气混合进行辅助通气或控制通气。在注射硫喷妥钠和维库溴铵2分钟后尝试进行持续30秒的喉镜检查。接受生理盐水的患者在气管插管时收缩压和舒张压、心率以及血浆儿茶酚胺浓度显著升高。使用任何一种钙通道阻滞剂治疗的患者,血压升高均有所减轻。维拉帕米的效果最佳,它减弱了心率的升高,尽管尼卡地平似乎增强了心动过速。所有三种药物均未能抑制气管插管引起的血浆儿茶酚胺浓度升高。这些结果表明,静脉推注0.1毫克/千克维拉帕米比0.2毫克/千克地尔硫䓬或30微克/千克尼卡地平更有效地控制与插管相关的高血压和心动过速,并且这些预防作用不是由抑制儿茶酚胺反应引起的。